At a Glance

  • PCT provides development, manufacturing and delivery of cell-based therapies for an impressive and growing list of established cell therapy leaders
  • Lead immuno-oncology program (Phase 3 study in metastatic melanoma) with Fast Track and Orphan Drug designations and a SPA (Tumor cell/dendritic cell technology)
  • Additional platforms for autoimmune disorders (Treg cells) and multiple ischemic repair indications (CD34+ expressing cells)
  • Highly experienced management and scientific team

Stock Quote

Exchange NASDAQ (US Dollar)
Change (%)
+0.03 (2.24%)
Data as of Nov 25, 1:08PM EST
Minimum 20 minute delay for quote.


Corporate Profile PDF

Corporate Presentation PDF